{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:02:17Z","timestamp":1787612537945,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid eye disease (TED) is a potentially disfiguring and sight-threatening autoimmune (AI) orbitopathy, affecting up to 400,000 people in the UK. There are no accurate early predictors of TED severity. Although polyautoimmunity has been shown to affect AI disease severity, its influence on TED severity has never been investigated. The prevalence of polyautoimmunity among TED patients is also unclear, with discordant results reported in the literature. This study evaluates the prevalence of non-thyroid\/\u201cother\u201d AI (OAI) conditions in an ethnically diverse TED cohort and assesses how polyautoimmunity affects TED severity and activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study of patients presenting to multidisciplinary TED clinics across three North-West London hospitals between 2011 and 2019. Data collected included: 1) demographics; 2) OAI conditions and management; 3) endocrine management of thyroid dysfunction; 4) details of TED and clinical activity score at presentation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two hundred and sixty-seven patients with a median age of 46 (35\u201354) years were included, 79.4% were female and 55% were Black, Asian and minority ethnic (BAME). Thirty-seven patients (13.9%) had OAI conditions, with rheumatoid arthritis (3.7%), vitiligo (3.0%) and psoriasis (3.0%) among the most prevalent. Of patients with OAI conditions, 43.2% (16\/37) required immunosuppression prior to TED onset. Non-immunosuppressed patients with OAI conditions had a significantly higher clinical activity score at presentation than TED-only and previously immunosuppressed patients (p=0.02). No significant differences were observed in thyroid receptor antibody titers between these groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study finds a 13.9% prevalence of OAI conditions among TED patients. Patients with OAI conditions overall have a tendency for more severe and significantly more clinically active TED than those without OAI conditions. Larger, prospective studies are warranted to further evaluate polyautoimmunity as an early predictor of TED severity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2021.644200","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T01:37:50Z","timestamp":1614908270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Association of Other Autoimmune Diseases With Thyroid Eye Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Mary","family":"Kelada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parizad","family":"Avari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Akishar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajni","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Bravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Meeran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/isbn.978-3-8055-8343-5","volume-title":"Graves\" orbitopathy : a multidisciplinary approach","author":"Wiersinga","year":"2007"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2011.10.005","article-title":"Epidemiology of Graves\u2019 orbitopathy (GO) and relationship with thyroid disease","volume":"26","author":"Lazarus","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/bmb\/ldr030","article-title":"The epidemiology of thyroid disease","volume":"99","author":"Vanderpump","year":"2011","journal-title":"Br Med Bull"},{"key":"B4","article-title":"Prevalence de l\u2019ophtalmopathie dans la maladie de basedow. Suivi des malades a un an apres la decouverte de leur hyperthyroidie","volume":"17","author":"Vangheluwe","year":"1994","journal-title":"J Fr Ophtalmol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30579-4","article-title":"Long-term follow-up of Graves ophthalmopathy in an incidence cohort","volume":"103","author":"Bartley","year":"1996","journal-title":"Ophthalmology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.88.1.75","article-title":"Assessing quality of life in Australian patients with Graves\u2019 ophthalmopathy","volume":"88","author":"Park","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3119","article-title":"Public health relevance of graves\u2019 orbitopathy","volume":"98","author":"Ponto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2017.1280057","article-title":"Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit","volume":"36","author":"Mellington","year":"2017","journal-title":"Orbit"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.12688\/f1000research.11535.1","article-title":"Recent advances in understanding autoimmune thyroid disease: The tallest tree in the forest of polyautoimmunity","volume":"6","author":"Bliddal","year":"2017","journal-title":"F1000Research"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000117914","article-title":"New Strategies in the Management of Parkinson\u2019s Disease: A Biological Approach Using a Phospholipid Precursor (CDP-Choline)","volume":"8","author":"Agnoli","year":"1982","journal-title":"Neuropsychobiology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0456","article-title":"Recurrent Pregnancy Loss in Women with Hashimoto\u2019s Thyroiditis with Concurrent Non-Endocrine Autoimmune Disorders","volume":"30","author":"Cellini","year":"2020","journal-title":"Thyroid"},{"key":"B12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/01.md.0000216817.35937.70","article-title":"Vasculitis in Systemic Lupus Erythematosus","volume":"85","author":"Ramos-Casals","year":"2006","journal-title":"Medicine (Baltimore)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1995.tb00432.x","article-title":"Associated autoimmune diseases in myasthenia gravis A population-based study","volume":"91","author":"Christensen","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.2.3749","article-title":"Mild Clinical Expression of Myasthenia Gravis Associated with Autoimmune Thyroid Diseases*","volume":"82","author":"Marin\u00f3","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090815","article-title":"Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: Results from 2 large cohorts of European Caucasian patients","volume":"37","author":"Avouac","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e318030b06b","article-title":"Association Between Thyroid Autoimmune Dysfunction and Non-Thyroid Autoimmune Diseases","volume":"23","author":"Cruz","year":"2007","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.10.001","article-title":"The association of other autoimmune diseases in patients with Graves\u2019 disease (with or without ophthalmopathy): Review of the literature and report of a large series","volume":"18","author":"Ferrari","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0475","article-title":"Role of the underlying thyroid disease on the phenotype of graves\u2019 orbitopathy in a tertiary referral center","volume":"25","author":"Leo","year":"2015","journal-title":"Thyroid"},{"key":"B19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/rheumatology\/41.7.793","article-title":"The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century","volume":"41","author":"Symmons","year":"2002","journal-title":"Rheumatology"},{"key":"B20","unstructured":"Thyroid disease and autoimmune diseases\n            FrancoJ-S\n            Amaya-AmayaJ\n            AnayaJ-M\n          2013"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072819","article-title":"Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis","volume":"67","author":"Farag\u00f3","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am J Hum Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science (80- )"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2190","article-title":"Interleukin (IL)-23 Receptor Is a Major Susceptibility Gene for Graves\u2019 Ophthalmopathy: The IL-23\/T-helper 17 Axis Extends to Thyroid Autoimmunity","volume":"93","author":"Huber","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/08916930802422265","article-title":"Association studies of the IL-23R gene in autoimmune thyroid disease in the Japanese population","volume":"42","author":"Ban","year":"2009","journal-title":"Autoimmunity"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12166","article-title":"Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms","volume":"168","author":"Gey","year":"2013","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaad.2015.08.063","article-title":"Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study","volume":"74","author":"Gill","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000354607","article-title":"Comorbidities associated with vitiligo: A ten-year retrospective study","author":"Sheth","year":"2014","journal-title":"Dermatology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/254319","article-title":"Introducing Polyautoimmunity: Secondary Autoimmune Diseases No Longer Exist","volume":"2012","author":"Rojas-Villarraga","year":"2012","journal-title":"Autoimmune Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40662-014-0009-8","article-title":"An overview of thyroid eye disease","volume":"1","author":"McAlinden","year":"2014","journal-title":"Eye Vis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0282-1","article-title":"Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves\u2019 orbitopathy: a case series","volume":"33","author":"Roos","year":"2019","journal-title":"Eye"},{"key":"B32","unstructured":"GOV.UK Ethnicity facts and figures"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-018-9478-8","article-title":"Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties","volume":"19","author":"Koch","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01293-7","article-title":"Management of Graves\u2019 hyperthyroidism and orbitopathy in time of COVID-19 pandemic","volume":"43","author":"Bartalena","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B35","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/ddg.14169","article-title":"COVID-19 and immunological regulations \u2013 from basic and translational aspects to clinical implications","volume":"18","author":"Sch\u00f6n","year":"2020","journal-title":"JDDG J der Dtsch Dermatologischen Gesellschaft"},{"key":"B36","unstructured":"TED Immunosuppression advice during Covid-19 \u2013 BOPSS"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.644200\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T01:37:56Z","timestamp":1614908276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.644200\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":36,"alternative-id":["10.3389\/fendo.2021.644200"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.644200","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]},"article-number":"644200"}}